摘要
目的:研究希罗达为基本药物的同步放化疗治疗胃癌D1/D2根治术的临床效果。方法:112例胃癌D1/D2根治术后的患者,在放疗期间(45Gy/25次),接受奥沙利铂与希罗达方案化疗(希罗达1000mg/m2,2次/d,d1-14,奥沙利铂100 mg/m2,d1),共4周期。选择同时期资料相似且化疗方案相同的110例患者做对照研究。结果:同步放化疗组与对照组1、2、3年总生存率分别为71.4%、61.6%、50.9%和70.0%、51.8%、36.4%(P=0.058);无复发生存率分别为67.0%、58.9%、46.4%和60.9%、37.3%、28.2%(P=0.003)。两组的主要毒性为1/2级血液学及胃肠道毒性。同步放化组发生3/4级白细胞减少为17.9%,恶心呕吐为6.3%,腹泻为4.5%;对照组发生3/4级白细胞减少为10.9%,恶心呕吐为2.7%,腹泻为2.7%。全组无3/4级手足综合征。结论:奥沙利铂与希罗达联合放疗治疗胃癌D1/D2根治术后患者,可以提高无复发生存率,毒性反应可以耐受。
Objective：To investigate the efficacy and toxicity of postoperativechemoradiation using oxaliplatin chemotherapy and oral capecitabine during radiation for gastric cancer following D1/D2 curative resection.Methods：One-hundred and twelve patients with gastric cancer who underwent potentially D1/D2 curative resection,accepted oxaliplatin chemotherapy and oral capecitabin（capecitabine 1000mg/m2,twice a day,d1-14;oxaliplatin 100 mg/m2,d1,total 4 cycles） during radiation（45Gy/25f）.We compared survival in these patients with 110 gastric cancer patients who had similar history and received a same chemotherapy regimen.Results：1-year,2-year,and 3-year overall survival rates of patients receiving concurrent chemoradiotherapy were 71.4%,61.6%,and 50.9%,respectively,whereas for gastric cancer patients receiving chemotherapy alone,the survival rates were 70.0%,51.8%,and 36.4%,respectively（P=0.058）;the 1-year,2-year,and 3-year disease-free survival rates for gastric cancer patients receiving concurrent chemoradiotherapy were 67.0%,58.9%,and 46.4%,respectively.Gastric cancer patients receiving chemotherapy alone exhibited a survival rate of 60.9%,37.3%,and 28.2%,respectively（P =0.003）.The major side response was grade 1/2 haematological and gastrointestinal toxicity.Grade 3/4 toxicities in chemoradiotherapy group included leucopenia in 17.9%,nausea/vomiting in 6.3% and diarrhea in 4.5%,in control group included leucopenia in 10.9%,nausea/vomiting in 2.7% and diarrhea in 2.7%.Neither grade 3/4 hand foot syndrome nor treatment related death were observed.Conclusion：Oxaliplatin chemotherapy and oral capecitabine during radiation for gastric cancer following D1/D2 curative resection could increase disease-free survival rate,and with less toxicity.
出处
《现代肿瘤医学》
CAS
2012年第12期2552-2555,共4页
Journal of Modern Oncology
基金
淮安市科技支撑计划项目基金(编号:HAS2011031)
南京医科大学附属淮安第一医院基金(编号:HAYY2009015)
关键词
胃癌
希罗达
奥沙利铂
同步放化疗
gastric cancer
capecitabin
oxaliplatin
concurrent chemoradiotherapy
